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Methylene blue (MB) is frequently used as an antidote in treating methemoglobinemia (1) because it facilitates the reducing activity of the NADPH-dependent methemoglobin reductase system in erythrocytes (2). However, MB absorbs strongly between 550 and 700 nm ( Fig. 1 530, 536, 542, 548, 554, 560, 566, 572, 578, 584, 590, 604, 612, 622, 630, 640 , and 648 nm.
Blood was collected from five healthy volunteers with informed consent. Because the study involved only blood sampling, Institutional Ethics Committee Review was not required in France.
The five samples were combined to obtain 120 mL of pooled blood, which were then separated into three 40-mL fractions:
-Fraction N, which had no enrichment in CO or MetHb.
-Fraction CO, which was enriched in CO by tonometry with use of an IL 237 tonometer (Instrumentation Laboratory) and CO in nitrogen, 10 mL/L (Société Cosma, Igny 91430, France).
Because of the time required to analyze a large number of samples, the tonometry was carried out separately on four 10-mL specimens just before analysis.
-Fraction Met, which was treated with 4 mg of hydroquinone (Prolabo, Paris, France) to obtain samples enriched in MetHb. Hydroquinone, a known inducer of MetHb, was selected for its lack of absorbance in the spectral range of hemoglobin. Again, this enrichment step was carried out on four 10-mL specimens just before analysis.
Each fraction was separated into aliquots. Four aliquots were adulterated with MB by dilution with a stock 10 g/L solution (Pharmacie Centrale des Hôpitaux de Paris, Paris, France) to obtain final concentrations of 0.1, 0.25, 0.50, and 1 g/L. We then added 1.0 mL of one of these solutions to 9.0 mL of blood to obtain a blood MB concentration of 10, 25, 50, or 100 mg/L. These MB concentrations were chosen to correspond to the plasma concentrations clinically anticipated when MB is slowly injected intravenously as 5-25 mL of a 10 g/L solution (the 100 mg/L concentration is rarely attained). Four control aliquots were prepared for each fraction as well, the MB being replaced with NaCl, 9 g/L. Each adulterated sample was compared with its own control, and measurement was performed immediately after treatment of the blood with either MB or NaCl.
Measurements were performed in triplicate with all six CO-Oximeters.
The tHb concentrations of controls measured by CO-Oximetry were 146 g/L. The COHb and
MetHb percentages of control specimens obtained from CO-Oximeters were respectively 1.05-1.55%
and 0.50-0.55% for the N samples, 23.1-36.6% and 0.1% for the CO samples, and 0.9-1.2% and 4.6-14.5% for the Met samples.
Using uncorrected data, we calculated the difference, negative or positive, between the mean of three values of the adulterated specimen and the mean for the corresponding control. The results (Table 1 ) Given that the known concentration of MetHb in these specimens is 0.5%, this would mean a relative error of 8500%! Large negative differences are observed as well. For instance, in samples with small percentages of COHb or MetHb, negative readings for samples adulterated with MB result in negative tHb percentages. In the CCD 270 results for the untreated (N) control and the specimen adulterated with MB (100 mg/L), the reported MetHb decreased from 0.5% to −8.5%-giving an absolute difference of −9%, but a relative error of 1800%. Furthermore, one sample adulterated with 100 mg/L MB gave a result >100% (CCD 270 O 2 Hb result for specimen Met) with a difference of +26.5%.
Several of the AVL 912 data points are missing, because the software for that analyzer eliminates most of the unreasonable results.
In interpreting the clinical significance of these findings, the relative errors are of greater importance, Indeed, one must take into account several types of problems of analysis, i.e., spectral order and software.
Regarding spectral order, analysis of a mixture of the four major derivatives of hemoglobin presupposes a spectral measurement of four wavelengths followed by a mathematical treatment of the signals. To correct for any eventual interference, one must make these measurements at other wavelengths and integrate into the system of calculation the absorption data specific to the interfering substance. MB absorbs strongly at 600-700 nm and more weakly at 550-600 nm (Fig.   1 ). Thus, its presence mainly affects the determination of MetHb near 620 nm and, more weakly, determinations of the other hemoglobin derivatives near that wavelength. This interference may be observed with the IL 482, which works uniquely at four wavelengths: MB absorbance at 626 nm simulates the presence of MetHb, resulting in a large increase for this derivative and consequently for tHb. This positive error for MetHb results in overcorrection for the other derivatives in the calculation system, so the values reported for them are too small.
The importance of software-related errors can be appreciated by comparing the results reported by the OSM3 and ABL 520, which are identical instruments; in the absence of an alternative explanation from the manufacturer, we believe the differences (error) in reported results may be attributed to differences in the software, which calculates the contributions of the various hemoglobin species. All CO-Oximeters tested other than the IL 482 measure at several wavelengths in the 630-670-nm region, which might be used to correct for MB. Generally, however, these wavelengths are used to correct for turbidity, and no instrument takes into account the absorption of MB in their calculation program. The corrections are therefore poorly adapted to the presence of MB and may produce errors of potentially significant magnitude (Table 1 ) . The AVL 912 system of calculation eliminates the most perturbed results, explaining the great number of missing values in Table 1 .
The effect of MB on measured tHb concentrations deserves further comment. The IL 482 apparently detects MB as an increase in the peak at 626 nm, registering it as an increase in MetHb and, consequently, in tHb. The other instruments, which measure near the maximum for MB absorption (650-700 nm), apparently recognize this peak outside the maximum range of hemoglobin as "nonhemoglobin" and correct the tHb downward.
We conclude, therefore, that these six CO-Oximeters should not be used to determine the concentration of hemoglobin derivatives in blood samples containing MB. This is particularly important in cases of methemoglobinemia, because the samples with high proportions of MetHb give the most affected results (Table 1 ) . Furthermore, pending further refinements, CO-Oximetry cannot be safely used clinically to evaluate the efficacy of treatment of methemoglobinemia with MB.
View larger version:
In this page
In a new window Figure 1 .
Spectra of hemoglobin derivatives and methylene blue.
The absorbance of MB in physiological (isotonic) saline solution peaks at 663 nm.
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Differences (absolute errors) between MB-adulterated blood specimens and controls.
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